Sharemaestro Newsreel

Earnings call transcript: Teleflex beats Q2 2026 EPS, but shares slip premarket

Pulse Biosciences earnings missed by $0.08, revenue fell short of estimates

Dentsply Sirona Q2 2026 Earnings: Sales Decline as GAAP Margins Recover

Dentsply Sirona reported a Q2 2026 net sales decline of 4.1% to $898 million, though GAAP diluted EPS improved to $0.18 from a prior-year loss, largely due to the absence of impairment charges. While GAAP gross margins and operating cash flow increased significantly, constant-currency …

Utah Medical Products Inc (UTMD) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article from TradingKey provides an earnings forecast for Utah Medical Products Inc (UTMD), focusing on future EPS and revenue growth estimates. It includes a snapshot of the company's current stock performance, market capitalization, and P/E ratio, alongside a list of peer companies for …

ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops

Align Technology Inc (ALGN) Stock Down 3.2% -- Now Undervalued? GF Score: 89/100

Align Technology Inc (ALGN) shares recently dropped by 3.2%, bringing its current price to $169.08. Despite this, the stock is considered undervalued with a GF Value™ estimate of $228.51, and boasts a strong GF Score™ of 89/100, indicating robust fundamentals. While profitability and valuation …

Is AptarGroup (ATR) Still Cheap As Sales Rise But Earnings Slip?

KORU Medical Systems (NASDAQ:KRMD) Announces Quarterly Earnings Results

LeMaitre management to meet investors at virtual Aug. 11 event

LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its management will participate in investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026. The event will be held in a virtual format. The company specializes in devices …

ResMed (RMD) Q4 Earnings and Revenues Top Estimates

ResMed (RMD) exceeded Q4 earnings and revenue estimates, reporting $2.95 per share against a consensus of $2.9 and revenues of $1.46 billion, surpassing estimates by 0.17%. Despite these positive results and outperforming EPS estimates for four consecutive quarters, the stock has underperformed the S&P …

NASDAQ: MDLN Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Medline Inc. (NASDAQ: MDLN) following significant FDA warning letters regarding manufacturing practice violations. Medline's stock price dropped over 7% after the initial FDA news and an additional 12% after disappointing …

Solventum Corp stock hits 52-week high at 89.35 USD By Investing.com

Solventum Corp (NYSE: SOLV) stock reached a 52-week high of $89.35, trading near its peak with a market capitalization of $15.15 billion and an attractive P/E ratio of 9.3. The company has seen a 21.57% increase in stock value over the past year, reflecting …

Becton Dickinson (NYSE: BDX) director awarded deferred stock rights

Becton Dickinson director Carrie L. Byington was granted 94 rights to Common Stock under the BD Deferred Compensation Plan, with each right valued at $165.62. This transaction increases her total plan rights to 3,810, including those acquired through dividend reinvestment. These rights convert one-for-one …

Earnings Flash (ICUI) ICU Medical, Inc. Reports Q2 Revenue $551.7M, vs. FactSet Est of $533.4M

ICU Medical, Inc. (ICUI) announced Q2 2026 revenue of $551.7 million, surpassing the FactSet estimate of $533.4 million. The company also reported Q2 adjusted EPS of $2.37 per share, exceeding the FactSet estimate of $1.91, and has lifted its 2026 guidance. This financial performance …

DENTSPLY SIRONA ($XRAY) Releases Q2 2026 Earnings, Stock Rises

Dentsply Sirona (NASDAQ:XRAY) Beats Q2 CY2026 Sales Expectations

Nyxoah (ENXTBR:NYXH) Stock Faces Cash Burn Questions After Sales Surge

Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q2 Revenue $0.4M, vs. FactSet Est of $533K

Pulse Biosciences, Inc. (PLSE) reported its Q2 revenue at $0.4 million, falling short of FactSet's estimated $533K. The company's stock, PLSE, is listed on Nasdaq in the Advanced Medical Equipment & Technology sector. The article also highlights recent news, including their Q2 earnings call, …

BioLife Solutions (NASDAQ: BLFS) plans cash-stock merger with Repligen

BioLife Solutions (NASDAQ: BLFS) has reported strong Q2 2026 financial results, with revenue reaching $28.5 million and net income from continuing operations at $45.1 million, largely due to a significant income tax benefit. The company also announced a cash-and-stock merger agreement with Repligen, where …

DENTSPLY SIRONA (XRAY): First Eagle discloses 851,347-share position in 13G/A

First Eagle Investment Management, LLC has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 851,347 shares in DENTSPLY SIRONA Inc. (XRAY). This position represents 0.4% of the company's common stock, keeping First Eagle below the 5% ownership threshold. The filing indicates First …

Azenta, Inc. 3Q 2026: Revenue $161.18M, EPS $0.05— 10-Q Summary

Azenta, Inc. reported strong third-quarter 2026 results, with revenue increasing 12% year-over-year to $161.18 million and diluted EPS reaching $0.05, a significant improvement from a loss in the prior year. The company returned to a net income of $2.46 million, driven by growth in …

KORU Medical (KRMD) CCO vests 75,000 RSUs and withholds shares for taxes

KORU Medical Systems' Chief Commercial Officer, Adam R. Kalbermatten, vested 75,000 Restricted Stock Units (RSUs) on July 28, 2026. Simultaneously, 25,483 shares were withheld at $4.26 per share to cover tax obligations. These transactions were reported as direct holdings and were not part of …

Earnings Flash (RMD) Resmed Inc. Posts Q4 Adjusted EPS $2.95 per Share, vs. FactSet Est of $2.89

Resmed Inc. (RMD) reported Q4 adjusted EPS of $2.95, surpassing the FactSet estimate of $2.89. The company's fiscal Q4 revenue was $1.46 billion, matching FactSet's estimate. Despite the positive earnings and revenue growth, ResMed's shares fell by 5%, indicating a perceived slowdown in growth.

[10-Q] BECTON DICKINSON & CO Quarterly Earnings Report

Becton, Dickinson and Company (BDX) has filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. Key highlights include the completion of the spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation, generating a …

Earnings Flash (BLFS) BioLife Solutions, Inc. Reports Q2 Revenue $28.5M, vs. FactSet Est of $27.8M

BioLife Solutions, Inc. (BLFS) announced its Q2 revenue of $28.5 million, surpassing the FactSet estimate of $27.8 million. The company's stock, listed on Nasdaq, closed at $33.93 on August 6th, marking a 0.38% increase for the day. This positive earnings report follows a series …

BIOLIFE SOLUTIONS ($BLFS) Releases Q2 2026 Earnings

Earnings Flash (XRAY) DENTSPLY SIRONA Inc. Reports Q2 Revenue $898.0M, vs. FactSet Est of $889.9M

DENTSPLY SIRONA Inc. (XRAY) reported its Q2 revenue at $898.0 million, surpassing FactSet's estimate of $889.9 million. The company is a diversified manufacturer of professional dental products and technologies, offering comprehensive solutions across various dental segments. The report also highlights recent company news, including …

Earnings Flash (XRAY) DENTSPLY SIRONA Inc. Posts Q2 Adjusted EPS $0.52 per Share

DENTSPLY SIRONA Inc. (XRAY) announced its Q2 adjusted EPS of $0.52 per share. This earnings flash follows a previous report that the company's Q2 revenue was $898.0M, exceeding FactSet estimates of $889.9M. The company is a diversified manufacturer of professional dental products and technologies.

BRIEF-Dentsply Sirona Q2 Revenue USD 898 Million Vs. IBES Estimate USD 889.8 Million

Dentsply Sirona announced its Q2 revenue reached USD 898 million, surpassing the IBES estimate of USD 889.8 million. This brief report highlights the company's financial performance relative to analyst expectations.

Earnings Flash (RMD) Resmed Inc. Reports Q4 Revenue $1.46B, vs. FactSet Est of $1.46B

Resmed Inc. (RMD) reported its Q4 revenue at $1.46 billion, which matched the FactSet estimate. This financial update indicates the company's performance aligned with market expectations for the quarter. The news was released by MT Newswires.

Nephros says its service offerings nearly tripled during Q2

Nephros (Nasdaq: NEPH) reported record second-quarter 2026 net revenue of $6.0 million, a 36% increase year-over-year, with core programmatic revenue growing 27%. The company's service offerings nearly tripled compared to the prior year, reflecting increased customer demand for installation, replacement, and water management support. …

Peter Farrell Sells 8,000 Shares of ResMed (NYSE:RMD) Stock

ResMed director Peter Farrell sold 8,000 shares of the company's stock for $1.8 million, reducing his holdings by 13.16% to 52,773 shares. The transaction, conducted under a Rule 10b5-1 trading plan, occurred on August 5th. ResMed's stock saw a slight increase of 0.1% to …

Resmed raises quarterly dividend 10% to $0.66 per share

Resmed reported strong Q4 FY2026 results with record revenue of $1.46 billion, up 9%, and non-GAAP EPS up 16%. For the full year FY2026, revenue increased 10% to $5.65 billion, with non-GAAP diluted EPS growing 17% to $11.17. The company also announced a 10% …

Teleflex Inc 2Q 2026: Revenue $570.33M, EPS $2.28— 10-Q Summary

Teleflex Inc. reported its second-quarter 2026 results, with revenue increasing to $570.33 million, a 28.9% rise year-over-year, largely due to the acquired VI Business and increased product volumes. However, diluted EPS fell to $2.28 from $2.77, and net income decreased by 18.7%. The company …

Bausch & Lomb Corp SEC Filing (Aug 6, 2026)

Bausch & Lomb Corp (BLCO) filed a Form 144 on August 6, 2026, indicating a proposed sale of 12,500 shares of common stock with an aggregate market value of $206,192.77. The shares were acquired on April 23, 2023, through restricted stock vesting as compensation. …

Stevanato Group (NYSE: STVN) targets 26.8% 2026 EBITDA margin

Stevanato Group reported strong Q2 2026 results with an 8% revenue increase and a 26% adjusted EBITDA margin, driven by growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and High Value Solutions. The company updated its full-year 2026 guidance, targeting a 26.8% adjusted …